Recent Posts
Deals•Feb 9, 2026
Galux Secures $29M Series B Funding Led by Yuanta
South Korean biotech Galux Inc., which uses generative AI for protein and antibody design, announced a $29 million Series B financing led by Yuanta. The fresh capital will support scaling of its AI‑driven biologics platform and recent collaboration with Boehringer Ingelheim. The round underscores growing investor interest in AI‑enabled drug discovery.
BioCentury
Deals•Jan 30, 2026
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
AstraZeneca announced a partnership with China's CSPC Pharmaceutical Group, paying $1.2 billion upfront for exclusive ex‑China rights to eight obesity and diabetes programs, including the GLP‑1R/GIPR agonist SYH2082. The total deal value is projected at $18.5 billion, marking one of AZ's largest...
BioCentury
Deals•Jan 21, 2026
Parabilis Secures $305M Crossover Round to Advance Helicon Platform
Parabilis Medicines announced a $305 million crossover financing round, giving the biotech company line of sight to Phase III trials for its lead candidate zolucatetide. The funding will support expansion of its Helicon platform into degrader, RIPTAC and radiopharmaceutical formats. The announcement...
BioCentury
Deals•Jan 7, 2026
Eli Lilly to Acquire Ventyx for $1.2B
Eli Lilly announced it will acquire Ventyx in a $1.2 billion transaction, expanding its neuroscience and immunology pipeline. The deal is driven by Ventyx’s NLRP3 programs with potential applications in pericarditis, Parkinson’s disease, and obesity‑associated cardiometabolic disease.
BioCentury
Deals•Jan 6, 2026
Amgen Acquires AML Candidate From UK Biotech Dark Blue
Amgen announced a deal to acquire an acute myeloid leukemia (AML) drug candidate from UK-based biotech Dark Blue. The terms of the transaction were not disclosed. The deal expands Amgen's oncology pipeline.
BioCentury
News•Dec 16, 2025
$12B-Plus in New Life Sciences Funds This Year
Venture capital activity in life sciences has surged in 2025, with at least 27 firms announcing new funds. Collectively, these vehicles have attracted more than $12 billion in capital, marking a record inflow for the sector. Notably, four of the funds...
By BioCentury
News•Dec 16, 2025
Elkedonia: Antidepressants that Act Downstream of Neurotransmitters
Elkedonia, a seed‑funded French biotech, is developing a novel class of antidepressants that target the transcription factor ELK1 to reboot neuroplasticity downstream of classic neurotransmitter pathways. The company announced a €5 million seed round led by European venture partners and presented...
By BioCentury
News•Dec 16, 2025
Obesity Data, Kymera and FDA Sentiment Survey Results — a BioCentury Podcast
Obesity therapeutics dominated the latest BioCentury podcast, with Eli Lilly unveiling new top‑line data for its triple‑agonist retatrutide, positioning it as a best‑in‑class weight‑loss candidate. Structure Therapeutics reported strong Phase IIb results for its oral GLP‑1, reigniting interest in non‑injectable options, while...
By BioCentury
News•Dec 16, 2025
Pursuing a Rare Autoimmune Disease Accelerated Kyverna’s Path to BLA
Kyverna Therapeutics announced that its lead autoimmune CAR‑T, mivocabtagene autoleucel (miv‑cel), achieved both primary and secondary endpoints in a registrational Phase II trial for stiff person syndrome. The data positions the therapy as the first autoimmune CAR‑T to pursue a Biologics...
By BioCentury
News•Dec 16, 2025
MHRA Deepens Global Strategy with Singapore Regulatory Pathway
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a regulatory innovation corridor with Singapore’s Health Sciences Authority, offering companies coordinated scientific advice from both regulators. Flagship Pioneering is the first industry partner, giving its biotech portfolio a...
By BioCentury
News•Dec 15, 2025
The Busiest Biotech Seed and Series A Investors of 2025
In 2025 more than a dozen venture capital firms have each disclosed at least five seed or Series A biotech investments, making them the busiest early‑stage investors of the year. BioCentury’s data shows that capital is flowing into a wide range...
By BioCentury
News•Dec 13, 2025
CEO Moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression
BioCentury reports a wave of CEO appointments across five life‑science firms. Prolynx named a former biotech COO to steer its next growth phase, while Centessa tapped a veteran pharma executive to accelerate its pipeline expansion. Kyowa Kirin promoted its internal R&D...
By BioCentury
News•Dec 12, 2025
Makary’s Embrace of Ideology, Conspiracies Puts FDA at Risk: A Perspective
FDA Commissioner Marty Makary is openly endorsing debunked conspiracy theories while linking drug approvals to political pricing deals and onshoring incentives. His recent podcast remarks claimed Lyme disease and AIDS originated from government labs, blurring the line between science and...
By BioCentury
News•Dec 12, 2025
EMA’s CHMP Backs New Medicines From Hansoh, Cytokinetics
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for five new drugs and vaccines in its December meeting. Two products originate from Chinese biotech Hansoh, while three are from U.S. firm Cytokinetics. The...
By BioCentury
News•Dec 12, 2025
BeOne Strengthens Its BTK Position at ASH
BeOne Medicines presented six‑year follow‑up data for its BTK inhibitor Brukinsa (zanubrutinib) at the ASH meeting, showing roughly 75% of treatment‑naïve chronic lymphocytic leukemia (CLL) patients remain progression‑free. The company also shared early results from a novel BTK degrader that...
By BioCentury
News•Dec 12, 2025
Lilly’s Triple Agonist Contender for Best-in-Class Weight Loss
Eli Lilly announced Phase III TRIUMPH-4 data for its triple‑agonist retatrutide, showing a 26.6% placebo‑adjusted weight loss after 68 weeks at the 12 mg weekly dose. The study enrolled 445 obese adults with knee osteoarthritis, and the highest dose translated to...
By BioCentury
News•Dec 12, 2025
BioCentury’s FDA Survey Reflects an Industry in Distress
BioCentury’s 2025 FDA survey paints a picture of deep distress across biopharma, flagging “inconsistency” as the sector’s most pressing worry. Respondents praised FDA staff effort but argued senior leadership decisions appear driven by political agendas rather than science. The perceived...
By BioCentury
News•Dec 12, 2025
Front Row with BioCentury: Inside the Turbulent Ride of Cell and Gene Therapy
Cell and gene therapy continues to attract attention despite a recent wave of setbacks that have slowed commercial momentum. Manufacturing complexities, heightened regulatory scrutiny, and pricing debates are creating a turbulent environment for developers. Nevertheless, breakthrough scientific data and expanding...
By BioCentury
News•Dec 12, 2025
Science Spotlight: Chinese Researchers Advance PROTAC Design
Chinese scientists have unveiled a next‑generation PROTAC scaffold that delivers oral bioavailability and heightened target selectivity. The platform successfully degrades previously undruggable proteins, including KRAS(G12C), and demonstrates tumor‑growth inhibition in mouse models. By integrating AI‑guided linker optimization, the researchers mitigated...
By BioCentury